✦ LIBER ✦

Results of Hysterectomy in Patients With Bulky Residual Disease at the End of Chemoradiotherapy for Stage IB2/II Cervical Carcinoma

✍ Scribed by Elie Azria; Philippe Morice; Christine Haie-Meder; Anne Thoury; Patricia Pautier; Catherine Lhomme; Pierre Duvillard; Damienne Castaigne

Book ID: 111771483
Publisher: Springer
Year: 2005
Tongue: English
Weight: 105 KB
Volume: 12
Category: Article
ISSN: 1068-9265
DOI: 10.1245/aso.2005.05.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Accuracy of magnetic resonance imaging i

Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy : Correlation of Radiologic Findings With Surgicopathologic Results

✍ Etienne Vincens; Corinne Balleyguier; Annie Rey; Catherine Uzan; Elise Zareski; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The evaluation of residual disease (RD) after chemoradiation therapy (CRT) in stage IB2/II cervical carcinoma conventionally is based on a clinical examination and magnetic resonance imaging (MRI) performed 3 to 8 weeks after the end of treatment. Very few studies have co

8000 ORAL Results of the GYNECO 02 Study

8000 ORAL Results of the GYNECO 02 Study, a FNCLCC Phase III Trial Comparing Hysterectomy Versus No Hysterectomy in Patients With a (Clinical and Radiological) Complete Response After Chemoradiation Therapy in IB2/II Stage Cervical Cancer

✍ Morice, P.; Rey, A.; Rouanet, P.; Romestaing, P.; Houvenaeghel, G.; Boulanger, J 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Para-Aortic Involvement and Interest of

Para-Aortic Involvement and Interest of Para-Aortic Lymphadenectomy after Chemoradiation Therapy in Patients with Stage IB2 and II Cervical Carcinoma Radiologically Confined to the Pelvic Cavity

✍ Yann Delpech; Christine Haie-Meder; Annie Rey; Yaelle Zafrani; Catherine Uzan; S 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 292 KB

791 Phase 2 study of neoadjuvant sorafen

791 Phase 2 study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676)

✍ Necchi, A.; Mariani, L.; Giannatempo, P.; Fina, E.; Nicolai, N.; Pennati, M.; Za 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 201 KB